Combination Chemotherapy in Treating Young Patients With Nonmetastatic Rhabdomyosarcoma

Summary

RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. It is not yet known which combination chemotherapy regimen is more effective in treating rhabdomyosarcoma.

PURPOSE: This randomized phase III trial is studying different combination chemotherapy regimens to compare how well they work in treating young patients with nonmetastatic rhabdomyosarcoma.

Conditions

• Sarcoma

Interventions

BIOLOGICAL

dactinomycin

DRUG

carboplatin

DRUG

cyclophosphamide

DRUG

doxorubicin hydrochloride

DRUG

etoposide

DRUG

ifosfamide

DRUG

topotecan hydrochloride

DRUG

vincristine sulfate

DRUG

vinorelbine tartrate

PROCEDURE

conventional surgery

RADIATION

radiation therapy

Sponsors & Collaborators

• Italian Association for Pediatric Hematology Oncology

  collaborator OTHER

• Children's Cancer and Leukaemia Group

  collaborator OTHER

• Dutch Childhood Oncology Group

  collaborator OTHER

• European Paediatric Soft Tissue Sarcoma Study Group

  lead OTHER

Principal Investigators

• Gianni Bisogno, MD · Azienda Ospedaliera di Padova

• Meriel Jenney, MD · Childrens Hospital for Wales

• Hans Merks, MD, PhD · Dutch Childhood Oncology Group

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Eligibility

Max Age

20 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2006-06-30

Primary Completion

2011-05-31

Countries

• Austria
• Belgium
• Denmark
• Ireland
• Spain
• Sweden
• Switzerland
• United Kingdom

Study Locations